Synthesis of tert-butyl (R)-3-(5-OXO-4,5-dihydro-1H-1,2,4-triazol-3- YL)piperidine-1-carboxylate in 75 gram quantity.
Ended Purchase Order Awarded Last action
- Contract number
- 75N95023P00723
- Awardee
-
Pointcare Systems Inc. UEI E4D5NF249E43
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $20,900
Award facts
- Opportunity
-
- Synthesis of tert-butyl (R)-3-(5-oxo-4, 5-dihydro-1H-1, 2, 4-triazol-3-yl)piperidine-1-carboxylate Special Notice · 75N95023Q00639 · Posted Aug 16, 2023
- Contract value 100% obligated
- $20,900.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- Set-aside
- Total Small Business
- Competition
- Competed under SAP · 5 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- India
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $10,000 | |
| Original award | $10,900 |
About this award
This firm fixed-price purchase order, valued at $10,900, was awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Pointcare Systems Inc. R&D Division, doing business as Chirosolve, for the synthesis of tert-butyl (R)-3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)piperidine-1-carboxylate in a 75 gram quantity with over 95% purity. The solicitation sought synthesis and delivery of the specified intermediate compound to support a project aiming to identify inhibitors of nicotinamide N-methyltransferase for treating ovarian cancer. Key deliverables under the contract include developing the chemical synthesis route, scaling up production, and reporting on characterization establishing purity over 95%. The award is designated for total small business and will be performed in India from September 2023 through December 2023.
Quick answers
Who was awarded contract 75N95023P00723?
75N95023P00723 was awarded to Pointcare Systems Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 8, 2023.
How much is contract 75N95023P00723 worth?
The government has obligated $20,900 on 75N95023P00723.
Which agency awarded contract 75N95023P00723?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95023P00723, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95023P00723 competed?
The extent of competition for 75N95023P00723 was competed under sap. The government received 5 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award